Identification of biomarkers to improve diagnostic sensitivity of sporadic colorectal cancer in patients with low preoperative serum carcinoembryonic antigen by clinical proteomic analysis

Chen, William Tzu Liang; Chang, Sheng Chi; Chiang, Hua Che; Tsai, Fuu Jen; Lo, Wan Yu

doi:10.1016/j.cca.2010.12.024

Cited by 15 publications

(8 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This protein is considered as potential biomarker for colorectal cancer. Chen et al have confirmed that the serum level of Alpha‐enolase in 26 of the 48 patients with colorectal cancer is threefold higher than that in healthy people by immunoblot analyses . LDH is also a well‐known biomarker.…”

Section: Resultsmentioning

confidence: 93%

Developing a strong anion exchange/RP (SAX/RP) 2D LC system for high-abundance proteins depletion in human plasma

et al. 2012

View full text Add to dashboard Cite

Human plasma is dominated by high-abundance proteins which severely impede the detection of low-abundance proteins. Unfortunately, now there is no efficient method for large-scale depletion of high-abundance proteins in human plasma. In this study, we developed a new strategy, strong anion exchange (SAX)/RP 2D LC system, which has potential for large-scale depletion of high-abundance proteins in human plasma. Separation gradients of the system were optimized to ensure an extensive separation of plasma proteins. Plasma was fractionated into 67 fractions by SAX. All these fractions were subjected a thorough separation by the 2D RPLC and 66 peaks with high UV absorption (>20 mAU) at 215 nm were collected. Proteins in these peaks were identified by LC-MS/MS analysis. Results showed that 83 proteins could be identified in these peaks, 68 among them were reported to be high- or middle-abundance proteins in plasma. All these proteins had definite retention times and were mapped in the 2D SAX-RP system, which resulted in accurate depletion of high-abundance proteins with ease. Our studies provide a convenient and effective method for large-scale depletion of high-abundance proteins and in-depth research in human plasma proteomics.

show abstract

Section: Resultsmentioning

confidence: 93%

Developing a strong anion exchange/RP (SAX/RP) 2D LC system for high-abundance proteins depletion in human plasma

et al. 2012

View full text Add to dashboard Cite

show abstract

“…Different proteomic technologies have been used to find new cancer biomarkers for CRC employed for risk prediction, diagnosis, prognosis, staging and monitoring treatment response of this disease. First proteomic studies focused on two‐dimensional electrophoresis (2‐DE) to characterize diseased vs control proteomes in combination with MALDI‐TOF MS or LC‐MS/MS . Nevertheless, these proteomic approaches involve hydrophobicity, size and solubility limitations of protein samples, and label‐free LC‐MS technologies have been used as an alternative approach in the search of CRC biomarkers .…”

Section: Discussionmentioning

confidence: 99%

“…16 in combination with MALDI-TOF MS 17,18 or LC-MS/MS. [19][20][21] Nevertheless, these proteomic approaches involve hydrophobicity, size and solubility limitations of protein samples, 22 and label-free LC-MS technologies have been used as an alternative approach in the search of CRC biomarkers. 21 Nowadays, SWATH technique provides comprehensive and permanent records of all detectable molecular species and this proteomic technology is emerging as a powerful tool for CRC research.…”

Section: Discussionmentioning

confidence: 99%

SWATH‐based proteomics reveals processes associated with immune evasion and metastasis in poor prognosis colorectal tumours

López‐Sánchez

Jiménez‐Izquierdo

Peñarando

et al. 2019

J Cellular Molecular Medi

View full text Add to dashboard Cite

Newly emerged proteomic methodologies, particularly data‐independent acquisition (DIA) analysis–related approaches, would improve current gene expression–based classifications of colorectal cancer (CRC). Therefore, this study was aimed to identify protein expression signatures using SWATH‐MS DIA and targeted data extraction, to aid in the classification of molecular subtypes of CRC and advance in the diagnosis and development of new drugs. For this purpose, 40 human CRC samples and 7 samples of healthy tissue were subjected to proteomic and bioinformatic analysis. The proteomic analysis identified three different molecular CRC subtypes: P1, P2 and P3. Significantly, P3 subtype showed high agreement with the mesenchymal/stem‐like subtype defined by gene expression signatures and characterized by poor prognosis and survival. The P3 subtype was characterized by decreased expression of ribosomal proteins, the spliceosome, and histone deacetylase 2, as well as increased expression of osteopontin, SERPINA 1 and SERPINA 3, and proteins involved in wound healing, acute inflammation and complement pathway. This was also confirmed by immunodetection and gene expression analyses. Our results show that these tumours are characterized by altered expression of proteins involved in biological processes associated with immune evasion and metastasis, suggesting new therapeutic options in the treatment of this aggressive type of CRC.

show abstract

“…EFEMP2) were better than CEA based on receiver operating characteristic analyses [28]. These new protein biomarkers might address the shortage of current CRC biomarkers, such as low CEA tumors seem to be inhibiting unique protein signatures that can be used as biomarkers for the detection of CRC in these patients with low CEA, for whom therefore serum CEA lacks sensitivity regarding the detection [62]. However, we have to keep in mind that CEA itself is not a good biomarker for CRC diagnosis.…”

Section: Opportunities and Challenges In Developing Proteomics-based mentioning

confidence: 99%

Developing proteomics‐based biomarkers for colorectal neoplasms for clinical practice: Opportunities and challenges

Luo

Wang

2013

Proteomics Clinical Apps

View full text Add to dashboard Cite

Colorectal cancer (CRC) arises from the normal colon epithelium through the accumulation of genetic mutations and epigenetic alterations that are associated with progression along the histological adenoma-adenocarcinoma sequence. Elucidating the molecular alterations underlying disease progression will not only provide insight into the behavior of the tumors, but also could lead to the discovery of useful biomarkers for diagnosis, monitoring treatment responsiveness, or predicting disease outcomes. In the past a few years, there have been several evaluating differentially expressed protein biomarkers by employing proteomics technologies coupled with mass spectrometry. In the current review, we will briefly summarize the results from selected recent studies using tissue or serum samples from CRC patients in the past 5 years and discuss the opportunities and challenges in translating these findings from the research setting to clinical practice.

show abstract

Identification of biomarkers to improve diagnostic sensitivity of sporadic colorectal cancer in patients with low preoperative serum carcinoembryonic antigen by clinical proteomic analysis

Cited by 15 publications

References 31 publications

Developing a strong anion exchange/RP (SAX/RP) 2D LC system for high-abundance proteins depletion in human plasma

Developing a strong anion exchange/RP (SAX/RP) 2D LC system for high-abundance proteins depletion in human plasma

SWATH‐based proteomics reveals processes associated with immune evasion and metastasis in poor prognosis colorectal tumours

Developing proteomics‐based biomarkers for colorectal neoplasms for clinical practice: Opportunities and challenges

Contact Info

Product

Resources

About